A clinical evaluation of the efficacy of a new hemostatic device for topical use in the surgical management of patients undergoing anticoagulant therapy

In oral surgery, the management of patients on anticoagulant therapy is still challenging because of the risk of uncontrolled bleeding and, if the therapy is discontinued, the possibility of undesired thromboembolic complications. The use of local hemostatic agents may be a viable alternative to overcome such problems. Pursuing this line, the aim of this randomized clinical trial was to evaluate the use of newly developed swelling matricx loaded with tranexamic acid to prevent postextractive bleeding in patients with no modification of oral anticoagulant therapy. The matrix is able to fit the tridimensional postexctractive alveolar cavity, thus assuring also a mechanical contribution to homeostasis. The potential of this new therapeutic approach for reducing hospitalization, removing the risk of infections, and lowering the number of hemorrhagic complications was demonstrated.